AP

ARS Pharmaceuticals, Inc.

SPRY·NASDAQ

$9.07

+1.9%
HealthcareBiotechnology

ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.

At a Glance

Live Snapshot
Market Cap$900.68M
EPS-1.7400
P/E Ratio-5.21
Earnings Date08/12/2026

spry

Cash and Cash Equivalents

Last Annual Value

41.32M

3-Year CAGR

-42%

5-Year CAGR

11%

10-Year CAGR

7%

AP

ARS Pharmaceuticals, Inc. Competitors Analysis of Cash and Cash Equivalents

SPRY · NASDAQ
CompanyCash and Cash Equivalents
CAGR 3Y
CAGR 5Y
CAGR 10Y
41.32M
-16.5%-7.2%N/A 
18.01M
-11.8%-30.3%-2.6%
SVRA logo
Savara Inc.
NASDAQ:SVRA
33.18M
7.7%-0.5%9.5%
149.10M
58.7%10.5%31.4%
57.98M
99.1%-13.2%N/A
25.18M
-10.5%6.6%N/A
PROK logo
ProKidney Corp.
NASDAQ:PROK
108.54M
21.4%39.5%N/A
77.39M
10.1%-23.8%N/A
RZLT logo
Rezolute, Inc.
NASDAQ:RZLT
94.11M
80.4%18.1%36.9%
AP

ARS Pharmaceuticals, Inc. Fair Value Envelope

SPRY · NASDAQ

Our analysis suggests that SPRY has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $9.07, this represents a potential HIDDEN relative to our calculated worth for ARS Pharmaceuticals, Inc..

Intrinsic Value
Current Price: $9.07